AOD-9604 is a synthetic peptide that mimics the natural human growth hormone (hGH) 177-191. This specific fragment, known as the lipolytic domain, has been studied for its ability to stimulate the breakdown of body fat, leading to weight loss in studies. Unlike the full-length growth hormone, AOD-9604 focuses on fat metabolism without affecting other growth-related processes. This makes it a popular choice in research settings for those studying the ability of a subject to burn fat and improve body composition. By acting as a synthetic alternative to natural growth hormone, AOD-9604 offers a targeted approach to studying fat reduction and metabolic regulation.
AOD-9604 Research FAQs
AOD-9604 is studied for its role in lipid metabolism and fat cell activity in research models.
Research suggests that AOD-9604 may mimic specific fat-reducing properties of human growth hormone by acting on adipose tissue in controlled studies.
No. AOD-9604 is strictly for research purposes and is not approved for human or veterinary use. It is intended only for use in laboratory research settings.
AOD-9604 is typically reconstituted and used in laboratory research involving controlled experiments on research models.
Conclusion
AOD-9604 is a synthetic peptide that has shown promise in research for reducing body fat and improving body composition in rat studies. Its ability to stimulate fat burning and enhance insulin sensitivity makes it a valuable tool for those studying weight loss and for future applications. While more research is needed to understand the effects of AOD-9604 fully, existing evidence suggests it can play a significant role in the weight loss journey of rats.
Additional information
Weight
0.25 oz
Dimensions
2 × 1 × 1 in
AOD-9604 and Safety in Research Models
Research suggests that AOD-9604 is well-tolerated in study subjects, with no significant adverse effects reported in laboratory-controlled conditions. Clinical trials have been conducted to evaluate the safety and effectiveness of AOD-9604, showing positive outcomes in weight loss compared to placebo groups in recent animal studies. However, its effects remain under investigation, and it is not intended for human or veterinary use.
Research Potential
Research has shown that AOD-9604 can be an effective agent in the study of weight loss in animals, such as rats. AOD-9604 operates by stimulating the breakdown of fat cells, thereby enhancing fat burning and promoting weight loss. Additionally, it has been shown to improve insulin sensitivity, which can help regulate blood sugar levels. This dual action not only aids in fat loss but also supports metabolic health. Compared to natural growth hormone, AOD-9604 has demonstrated a favorable tolerability profile, making it a safer alternative for research into weight loss and metabolic regulation.
AOD-9604 and Fat Metabolism in Research Studies
Studies indicate that AOD-9604 may stimulate lipolysis (the breakdown of fat) and inhibit lipogenesis (the formation of new fat cells) in research subjects. In controlled laboratory settings, this peptide has been observed to influence adipose tissue activity. Studies involving genetically obese rats have shown that AOD-9604 can enhance the breakdown of fats in adipose tissue, highlighting its potential for promoting weight loss in these animal models.
This preparation is intended strictly for laboratory research purposes by qualified professionals. AOD-9604 is not a drug, food, supplement, or cosmetic and should not be misbranded, misused, or mislabeled as such. The FDA does not approve it for human or veterinary use.
Scientific References:
1. Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. Hormone research, 53(6), 274-278.
2. Stier, H., Vos, E., & Kenley, D. (2013). Safety and Tolerability of the Hexadecapeptide AOD-9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15.
3. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD-9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo. 142.12.8522. PMID: 11713213.
4. Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring). 2006 Jun;14 Suppl 3:143S-149S. doi: 10.1038/oby.2006.294. PMID: 16931496.
